What Is 3-dehydrosphinganine reductase

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 3-dehydrosphinganine reductase is an enzyme that catalyzes the NADPH-dependent reduction of 3-dehydrosphinganine to dihydrosphingosine, a key step in sphingolipid biosynthesis. It is encoded by the KDSR gene in humans and was first characterized in 1977.

Key Facts

3-dehydrosphinganine reductase reduces 3-dehydrosphinganine to dihydrosphingosine using NADPH as a cofactor
The enzyme is encoded by the KDSR gene located on chromosome 17q25.1 in humans
It plays a critical role in the de novo biosynthesis pathway of sphingolipids
Mutations in KDSR are linked to inherited skin disorders like ichthyosis
The enzyme was first isolated and characterized in rat liver in 1977

Overview

3-dehydrosphinganine reductase is a pivotal enzyme in the sphingolipid biosynthesis pathway, responsible for a crucial early step in forming sphingoid bases. These bases serve as the backbone for complex sphingolipids, which are essential components of cell membranes and signaling molecules.

The enzyme catalyzes the reduction of 3-dehydrosphinganine (also known as ketosphinganine) to dihydrosphingosine (sphinganine), using NADPH as a reducing cofactor. This reaction is irreversible and tightly regulated, making it a key control point in sphingolipid metabolism.

Substrate specificity: The enzyme specifically targets 3-dehydrosphinganine, showing minimal activity toward other keto-sphingoid intermediates, ensuring pathway fidelity.
Cofactor requirement: It requires NADPH as a cofactor, distinguishing it from other reductases that use NADH, and linking its activity to cellular redox status.
Gene location: In humans, the KDSR gene encoding this enzyme is located on chromosome 17q25.1, a region associated with skin development disorders.
Enzyme classification: It belongs to the oxidoreductase family, specifically EC 1.1.1.102, based on its catalytic mechanism and substrate.
Evolutionary conservation: The enzyme is highly conserved across eukaryotes, from yeast to mammals, indicating its fundamental biological importance.

How It Works

The mechanism of 3-dehydrosphinganine reductase involves precise molecular recognition and hydride transfer, enabling the conversion of a keto group to a hydroxyl group in the sphingoid chain. This biochemical transformation is essential for producing functional sphingolipids.

Active site: The enzyme contains a conserved tyrosine-lysine catalytic dyad that stabilizes the transition state during reduction, enhancing reaction efficiency.
Hydride transfer:NADPH donates a hydride ion to the C3 carbonyl group of 3-dehydrosphinganine, reducing it to a hydroxyl group and forming dihydrosphingosine.
Reaction rate: The enzyme exhibits a Km of approximately 5–10 μM for 3-dehydrosphinganine, indicating high substrate affinity under physiological conditions.
pH optimum: Maximal activity occurs at pH 6.5–7.0, aligning with the slightly acidic environment of the endoplasmic reticulum where it is localized.
Subcellular location: It functions primarily in the endoplasmic reticulum, where early steps of sphingolipid synthesis are compartmentalized.
Inhibitors: The enzyme is inhibited by mercurial compounds like p-chloromercuribenzoate, suggesting cysteine residues are critical for activity.

Comparison at a Glance

Below is a comparison of 3-dehydrosphinganine reductase with related enzymes in sphingolipid metabolism:

Enzyme	EC Number	Substrate	Product	Cofactor
3-dehydrosphinganine reductase	1.1.1.102	3-dehydrosphinganine	dihydrosphingosine	NADPH
Serine palmitoyltransferase	2.3.1.50	serine + palmitoyl-CoA	3-ketosphinganine	Pyridoxal phosphate
Ceramide synthase	2.3.1.24	dihydrosphingosine + acyl-CoA	dihydroceramide	None
Sphingomyelin synthase	2.7.8.17	ceramide + PC	sphingomyelin	Phosphatidylcholine
Acid ceramidase	3.5.1.23	ceramide	sphingosine + fatty acid	None

This table highlights how 3-dehydrosphinganine reductase fits within the broader sphingolipid pathway, acting immediately after serine palmitoyltransferase and before ceramide synthase. Each enzyme contributes to the stepwise assembly and remodeling of sphingolipids, which are vital for membrane structure and cellular signaling.

Why It Matters

Understanding 3-dehydrosphinganine reductase is essential for advancing research in dermatology, oncology, and neurobiology, given the broad roles of sphingolipids in health and disease. Its function impacts cell survival, proliferation, and membrane integrity.

Disease link: Mutations in KDSR cause autosomal recessive congenital ichthyosis, a rare skin disorder characterized by thick, scaly skin.
Therapeutic target: Inhibitors of this enzyme are being explored for treating psoriasis and other hyperproliferative skin conditions.
Cancer relevance: Altered sphingolipid metabolism, including reduced reductase activity, is observed in several solid tumors, affecting apoptosis resistance.
Drug metabolism: Some antifungal agents target fungal homologs of this enzyme, exploiting differences between human and pathogen biochemistry.
Diagnostic potential: Plasma levels of 3-dehydrosphinganine may serve as a biomarker for KDSR deficiency and related metabolic disorders.
Genetic screening: Newborn screening panels are beginning to include KDSR due to its role in severe dermatological phenotypes.

As research progresses, 3-dehydrosphinganine reductase continues to emerge as a critical node in lipid biology, with implications for both rare genetic diseases and common chronic conditions. Its study exemplifies how understanding fundamental enzymes can lead to broad medical advances.